Ladenburg Thalmann reveals pivotal showcase on Crofelemer's rare disease trials

On December 18, 2024, a virtual Scientific Showcase will be held, hosted by Ladenburg Thalmann, focusing on Jaguar Health's clinical development activities for the treatment of rare diseases using crofelemer. This presentation will serve as a platform for discussing the ongoing clinical efforts targeting microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF), both of which are ultra-rare congenital disorders affecting patients, primarily in the US, EU, and Middle East/North Africa regions. The event is scheduled from 11:00 AM to 12:00 PM Eastern and is directed towards the financial and business community, highlighting the potential advancements and innovations in treating these specific ailments. Jaguar Health is making significant strides through various clinical efforts, which include three investigator-initiated trials and two Phase 2 studies exploring the efficacy of crofelemer for these rare diseases. The results from the investigator-initiated trials are anticipated to be available in the second quarter of 2025, informing stakeholders about the progress and effectiveness of treatments being developed. The emphasis on these initiatives aligns with the broader movement towards developing targeted therapies for conditions that have historically seen limited treatment options. The virtual event will feature contributions from Jaguar Health’s leadership, including Lisa Conte, the founder and CEO, and Pravin Chaturvedi, Chief Scientific Officer and Chair of the Scientific Advisory Board. Their participation underscores the importance of investor awareness and engagement while also showcasing the company’s dedication to advancing therapeutic options for patients suffering from such debilitating conditions. Additionally, this moment comes at a time when Jaguar Health has been recognized in the industry for its innovative approaches, including recent accolades received by Massimo Radaelli, who was named the "Best Pharmaceuticals Innovator of the Year - Europe." This recognition reflects the broader implications of Jaguar's commitment to addressing gaps in treatment for orphan and rare diseases, with ongoing efforts aimed at increasing access to crofelemer, especially in Europe. As diseases like MVID and SBS-IF remain complex and challenging to manage, the upcoming showcase could play a crucial role in establishing connections, sharing knowledge, and potentially paving the way for future collaborations that may lead to improved patient outcomes.